{"entity": "researcher", "timestamp": "2026-08-20T21:23:55.133Z", "family": "Gonz\u00e1lez", "given": "Ferm\u00edn E", "initials": "FE", "orcid": "0000-0002-4212-1009", "affiliations": ["Laboratory of Experimental Immunology & Cancer, Faculty of Dentistry, Universidad de Chile, Santiago 8380000, Chile."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/e9671a5793684845a35362cea70d03df.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/e9671a5793684845a35362cea70d03df"}}, "publications": [{"entity": "publication", "iuid": "a71c46f25a9c401b977281217cb18601", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/a71c46f25a9c401b977281217cb18601.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/a71c46f25a9c401b977281217cb18601"}}, "title": "Long-Term Survival and Immune Response Dynamics in Melanoma Patients Undergoing TAPCells-Based Vaccination Therapy.", "authors": [{"family": "Tittarelli", "given": "Andr\u00e9s", "initials": "A", "orcid": "0000-0003-4129-9734", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/4b33ae07f33248c2b87955e83d5fc6de.json"}}, {"family": "Pereda", "given": "Cristian", "initials": "C", "orcid": "0009-0000-1033-0247", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/aab236d1354243cc942b474809e714ec.json"}}, {"family": "Gleisner", "given": "Mar\u00eda A", "initials": "MA", "orcid": "0000-0002-4172-9709", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/fa028fc3b7b54583805e12ba55ef11da.json"}}, {"family": "L\u00f3pez", "given": "Mercedes N", "initials": "MN"}, {"family": "Flores", "given": "Iv\u00e1n", "initials": "I"}, {"family": "Tempio", "given": "Fabi\u00e1n", "initials": "F"}, {"family": "Lladser", "given": "Alvaro", "initials": "A", "orcid": "0000-0002-5576-1478", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/67fcde9ec88d497e91d5e64a2d785549.json"}}, {"family": "Achour", "given": "Adnane", "initials": "A", "orcid": "0000-0003-0432-710X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/65fba324156a4fcbafbe636e642587a9.json"}}, {"family": "Gonz\u00e1lez", "given": "Ferm\u00edn E", "initials": "FE", "orcid": "0000-0002-4212-1009", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/e9671a5793684845a35362cea70d03df.json"}}, {"family": "Dur\u00e1n-Aniotz", "given": "Claudia", "initials": "C", "orcid": "0000-0003-2503-8366", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/0f0c51284b534d0ab63339baa9f07682.json"}}, {"family": "Miranda", "given": "Juan P", "initials": "JP"}, {"family": "Larrondo", "given": "Milton", "initials": "M"}, {"family": "Salazar-Onfray", "given": "Flavio", "initials": "F", "orcid": "0000-0002-1848-5697", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9d4f0919a9b444a1a690c9fb6cb9c25f.json"}}], "type": "journal article", "published": "2024-03-27", "journal": {"title": "Vaccines (Basel)", "issn": "2076-393X", "volume": "12", "issue": "4", "issn-l": null}, "abstract": "Cancer vaccines present a promising avenue for treating immune checkpoint blockers (ICBs)-refractory patients, fostering immune responses to modulate the tumor microenvironment. We revisit a phase I/II trial using Tumor Antigen-Presenting Cells (TAPCells) (NCT06152367), an autologous antigen-presenting cell vaccine loaded with heat-shocked allogeneic melanoma cell lysates. Initial findings showcased TAPCells inducing lysate-specific delayed-type hypersensitivity (DTH) reactions, correlating with prolonged survival. Here, we extend our analysis over 15 years, categorizing patients into short-term (<36 months) and long-term (\u226536 months) survivors, exploring novel associations between clinical outcomes and demographic, genetic, and immunologic parameters. Notably, DTHpos patients exhibit a 53.1% three-year survival compared to 16.1% in DTHneg patients. Extended remissions are observed in long-term survivors, particularly DTHpos/M1cneg patients. Younger age, stage III disease, and moderate immune events also benefit short-term survivors. Immunomarkers like increased C-type lectin domain family 2 member D on CD4+ T cells and elevated interleukin-17A were detected in long-term survivors. In contrast, toll-like receptor-4 D229G polymorphism and reduced CD32 on B cells are associated with reduced survival. TAPCells achieved stable long remissions in 35.2% of patients, especially M1cneg/DTHpos cases. Conclusions: Our study underscores the potential of vaccine-induced immune responses in melanoma, emphasizing the identification of emerging biological markers and clinical parameters for predicting long-term remission.", "doi": "10.3390/vaccines12040357", "pmid": "38675738", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC11053591"}, {"db": "pii", "key": "vaccines12040357"}], "notes": [], "created": "2026-08-20T13:43:21.587Z", "modified": "2026-08-20T13:43:21.931Z"}]}